- Home
- TPST vs COCH Comparison
TPST vs COCH Comparison
Compare TPST & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TPST | COCH |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 24.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | COCH |
|---|---|---|
| Price | $2.94 | $0.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $12.50 | $9.50 |
| AVG Volume (30 Days) | 89.5K | ★ 185.9K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $0.64 |
| 52 Week High | $13.65 | $1.91 |
Technical Indicators
Market Signals| Indicator | TPST | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 31.43 | 43.75 |
| Support Level | $2.80 | $0.66 |
| Resistance Level | $3.20 | $0.75 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 51.25 | 21.05 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.